Hon. Anna G. Eshoo (D-CA), Co-Chair, Congressional Medical Technology Caucus
Hon. Erik Paulsen (R-MN), Co-Chair, Congressional Medical Technology Caucus
For an Informational Briefing on
The Value of Medical Innovation
Moderated by CHI President and CEO
David L. Gollaher, Ph.D.
Medical innovation – researching and discovering new treatments and cures for the world’s most dreaded diseases – is a highly complex and often misunderstood undertaking. But these efforts hold the future promise of helping patients around the world live longer, with less pain and more independence. Not only does medical innovation save and improve lives, but it also realizes significant cost savings and remains a driver of America’s workforce and economy.
As our nation is confronted with increasing healthcare costs, we must also acknowledge that medical innovations are a key part of the solution – not the problem. Indeed, the challenge we face today is how to ensure, in an increasingly unpredictable, uncertain and complex environment, that the life sciences sector continues to thrive, advancing science, creating new high-paying jobs, and developing new medicines and technologies for patients in need.
This multi-state briefing will include experts from the following life sciences communities:
Medical Device Innovation – Heather Keith, Chief Executive Officer, Strohl Medical
Biotechnology Innovation – Paul Hastings, President and Chief Executive Officer, OncoMed
Hybrid Technologies Innovation – Kelly Powers, Senior Vice President of Research & Development, Bard Access
Venture Capital: Investment in Research – Jonathan Leff, Partner, Deerfield Management
Innovation’s Impact on the Patient Community, Marc Boutin, J.D., Executive Vice President and Chief Operating Officer, National Health Council
Questions? Please contact Jenny Carey, CHI’s associate director of federal relations and programs (firstname.lastname@example.org or (202-974-6362)
This event is held in strict accordance with House and Senate Ethics rules. Food and refreshments of a nominal value will be provided as allowed by House Rule 25, clause 5(a)(3)(U) and Senate Rule 35.1(d)(1)